Signaturefd LLC Has $862,000 Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Signaturefd LLC increased its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 43.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 65,097 shares of the company's stock after purchasing an additional 19,786 shares during the period. Signaturefd LLC's holdings in Takeda Pharmaceutical were worth $862,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of TAK. Versant Capital Management Inc acquired a new stake in Takeda Pharmaceutical in the 4th quarter valued at $26,000. Wilmington Savings Fund Society FSB bought a new position in shares of Takeda Pharmaceutical during the third quarter valued at $40,000. BNP Paribas Financial Markets boosted its stake in shares of Takeda Pharmaceutical by 416.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company's stock valued at $46,000 after purchasing an additional 2,596 shares in the last quarter. Farther Finance Advisors LLC grew its holdings in shares of Takeda Pharmaceutical by 123.6% in the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock worth $47,000 after purchasing an additional 1,976 shares during the last quarter. Finally, Smithfield Trust Co increased its position in shares of Takeda Pharmaceutical by 76.9% during the 3rd quarter. Smithfield Trust Co now owns 3,428 shares of the company's stock worth $49,000 after purchasing an additional 1,490 shares in the last quarter. Institutional investors own 9.17% of the company's stock.

Takeda Pharmaceutical Price Performance

NYSE:TAK traded down $0.18 on Monday, reaching $15.02. The stock had a trading volume of 1,095,747 shares, compared to its average volume of 1,798,184. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $47.78 billion, a P/E ratio of 37.54, a price-to-earnings-growth ratio of 0.24 and a beta of 0.46. Takeda Pharmaceutical Company Limited has a 1-year low of $12.58 and a 1-year high of $15.31. The stock has a fifty day moving average price of $13.96 and a 200-day moving average price of $13.91.

Remove Ads

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. Research analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.